Immune checkpoint therapy for non-small-cell lung cancer: an update
1Yale Comprehensive Cancer Center, Yale School of Medicine, 333 Cedar Street WWW221, New Haven, CT 06520, USA.
Abstract:
The role of immunotherapy in treatment of non-small-cell lung cancer (NSCLC) has been gaining interest over the past few years. This has been driven primarily by promising results from trials evaluating antagonist antibodies that target co-inhibitory immune checkpoints expressed on tumor cells and immune cells within the tumor microenvironment. Immune checkpoints exist to dampen or terminate immune activity to guard against autoimmunity and allow for self-tolerance. However, tumors can take advantage of these immune checkpoint pathways to evade destruction. Antibodies that block inhibitory checkpoints, such as anti-CTLA-4, anti-PD1 and anti-PD-L1 antibodies have demonstrated delayed tumor growth and increased survival. Novel therapies are now investigating combining checkpoint inhibitors with chemotherapy, targeted therapy, radiation and vaccines to produce synergistic antitumor activity.
Insights
Immunotherapy using checkpoint inhibitors shows promise for treating non-small-cell lung cancer (NSCLC) by blocking immune evasion. Combining these therapies with other treatments may enhance antitumor activity and improve patient survival.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Non-small-cell lung cancer (NSCLC) treatment is evolving with immunotherapy.
- Immune checkpoints regulate immune responses but can be exploited by tumors to evade destruction.
- Tumor cells and immune cells express co-inhibitory immune checkpoints.
Purpose of the Study:
- To review the role of immunotherapy in NSCLC treatment.
- To highlight the mechanism of action of immune checkpoint inhibitors.
- To discuss novel combination therapies for synergistic antitumor activity.
Main Methods:
- Evaluation of antagonist antibodies targeting co-inhibitory immune checkpoints.
- Analysis of clinical trial data for anti-CTLA-4, anti-PD1, and anti-PD-L1 antibodies.
- Review of emerging combination strategies including chemotherapy, radiation, and vaccines.
Main Results:
- Immune checkpoint inhibitors have demonstrated delayed tumor growth in NSCLC.
- Therapies targeting CTLA-4, PD-1, and PD-L1 pathways have shown increased survival rates.
- Combination therapies are being investigated for enhanced antitumor effects.
Conclusions:
- Immunotherapy, particularly with checkpoint inhibitors, is a significant advancement in NSCLC treatment.
- Blocking immune checkpoints offers a strategy to overcome tumor-induced immune suppression.
- Future research focuses on combining immunotherapies with other modalities for improved efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies